Repligen restates 2023 and first-half 2024 results over $17.3 million payment timing
Repligen said its prior financial statements should no longer be relied upon and will be restated for 2023 and the first half of 2024, after a $17.3 million COVID-related customer cancellation payment was recognized in the wrong period. The company identified a material weakness in internal control over financial reporting, and its internal review is ongoing. Management reaffirmed 2024 revenue guidance of $627 million to $642 million, saying overall revenue and cash are unchanged.
Key points
- A $17.3 million payment received in April 2023 should have been deferred and recognized as products were delivered, with all open orders delivered by June 30, 2024.
- Restated full-year 2023 total revenue is $632.2 million versus $638.8 million as reported; restated 2023 GAAP income from operations is $48.0 million versus $54.6 million as reported.
- Restated first-half 2024 total revenue is $312.0 million versus $305.4 million as reported; restated first-half 2024 GAAP income from operations is $10.1 million versus $3.5 million as reported.
- The company identified a material weakness in internal controls over revenue recognition and said it may identify further changes to previously reported amounts.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 18, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.